{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:40:06Z","timestamp":1793814006897,"version":"4.6.1"},"reference-count":57,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,1,12]]},"published-print":{"date-parts":[[2026,6]]},"DOI":"10.2967\/jnumed.125.270872","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:55:16Z","timestamp":1772124916000},"page":"929-935","source":"Crossref","is-referenced-by-count":9,"title":["Quantitative PSMA PET Biomarkers for Predicting Response to\n                    <sup>177<\/sup>\n                    Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.2967","volume":"67","author":[{"given":"Iman","family":"Kiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Siri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahan","family":"Babaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mahdi","family":"Aliasghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Mohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salavati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2026060105301018000_67.6.929.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2026060105301018000_67.6.929.2","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.3390\/jcm14093067","article-title":"Prostate cancerresearch advances in early detection","volume":"14","author":"Czerw","year":"2025","journal-title":"J Clin Med."},{"key":"2026060105301018000_67.6.929.3","doi-asserted-by":"crossref","first-page":"101833","DOI":"10.1016\/j.canep.2020.101833","article-title":"Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database","volume":"69","author":"Thurin","year":"2020","journal-title":"Cancer Epidemiol."},{"key":"2026060105301018000_67.6.929.4","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3390\/biomedicines9091247","article-title":"Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Henriquez","year":"2021","journal-title":"Biomedicines."},{"key":"2026060105301018000_67.6.929.5","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol."},{"key":"2026060105301018000_67.6.929.6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026060105301018000_67.6.929.7","doi-asserted-by":"crossref","first-page":"102699","DOI":"10.1016\/j.ctrv.2024.102699","article-title":"177Lu-PSMA therapy in metastatic prostate cancer: an updated review of prognostic and predictive biomarkers","volume":"125","author":"Giunta","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"2026060105301018000_67.6.929.8","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-014-0315-z"},{"key":"2026060105301018000_67.6.929.9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2022.7070","article-title":"Cost-effectiveness analysis of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer","volume":"21","author":"Mehrens","year":"2023","journal-title":"J Natl Compr Canc Netw."},{"key":"2026060105301018000_67.6.929.10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/cancers14030647","article-title":"Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T","volume":"14","author":"Hartrampf","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2026060105301018000_67.6.929.11","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2026060105301018000_67.6.929.12","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MNM.0000000000001539","article-title":"Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET, a different perspective with quantitative parameters","volume":"43","author":"Aksu","year":"2022","journal-title":"Nucl Med Commun."},{"key":"2026060105301018000_67.6.929.13","doi-asserted-by":"crossref","first-page":"1066926","DOI":"10.3389\/fonc.2022.1066926","article-title":"Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA","volume":"12","author":"Assadi","year":"2022","journal-title":"Front Oncol."},{"key":"2026060105301018000_67.6.929.14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","article-title":"Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with lutetium-177-PSMA-617","volume":"57","author":"Crumbaker","year":"2023","journal-title":"Eur Urol Open Sci."},{"key":"2026060105301018000_67.6.929.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.09.014"},{"key":"2026060105301018000_67.6.929.16","doi-asserted-by":"crossref","first-page":"17588359231156392","DOI":"10.1177\/17588359231156392","article-title":"Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)","volume":"15","author":"Emmett","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2026060105301018000_67.6.929.17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s12149-022-01739-3","article-title":"The role of Ga68 PSMA PET\/CT imaging in Lu177 PSMA treatment planning in metastatic castration-resistant prostate cancer","volume":"36","author":"Erdogan","year":"2022","journal-title":"Ann Nucl Med."},{"key":"2026060105301018000_67.6.929.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178228"},{"key":"2026060105301018000_67.6.929.19","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301018000_67.6.929.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6"},{"key":"2026060105301018000_67.6.929.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267723"},{"key":"2026060105301018000_67.6.929.22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/cancers15020473","article-title":"Baseline [68Ga]Ga-PSMA-11 PET\/CT before [177Lu]Lu-PSMA-617 radioligand therapy: value of PSMA-uptake thresholds in predicting targetable lesions","volume":"15","author":"Groener","year":"2023","journal-title":"Cancers (Basel)."},{"key":"2026060105301018000_67.6.929.23","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","article-title":"SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T","volume":"50","author":"Hartrampf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301018000_67.6.929.24","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.3390\/cancers16152670","article-title":"Analysis of molecular imaging and laboratory baseline biomarkers in PSMA-RLT: whole-body total lesion PSMA (TLP) predicts overall survival","volume":"16","author":"Hein","year":"2024","journal-title":"Cancers (Basel)."},{"key":"2026060105301018000_67.6.929.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265242"},{"key":"2026060105301018000_67.6.929.26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12149-020-01567-3","article-title":"Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen","volume":"35","author":"Huang","year":"2021","journal-title":"Ann Nucl Med."},{"key":"2026060105301018000_67.6.929.27","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"2026060105301018000_67.6.929.28","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.1038\/s41598-024-61961-z","article-title":"Dual FDG\/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT","volume":"14","author":"Rosar","year":"2024","journal-title":"Sci Rep."},{"key":"2026060105301018000_67.6.929.29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301018000_67.6.929.30","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.7150\/thno.60222","article-title":"Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy","volume":"11","author":"Seifert","year":"2021","journal-title":"Theranostics."},{"key":"2026060105301018000_67.6.929.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267014"},{"key":"2026060105301018000_67.6.929.32","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/biomedicines10071575","article-title":"Baseline imaging derived predictive factors of response following [177Lu]Lu-PSMA-617 therapy in salvage metastatic castration-resistant prostate cancer: a lesion- and patient-based analysis","volume":"10","author":"van der Sar","year":"2022","journal-title":"Biomedicines."},{"key":"2026060105301018000_67.6.929.33","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00259-022-05974-8","article-title":"Individual radiosensitivity reflected by ?-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy","volume":"50","author":"Widjaja","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301018000_67.6.929.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264857"},{"key":"2026060105301018000_67.6.929.35","doi-asserted-by":"crossref","first-page":"17588359231157632","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2026060105301018000_67.6.929.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026060105301018000_67.6.929.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026060105301018000_67.6.929.38","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bju.16608","article-title":"Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis","volume":"135","author":"Chen","year":"2025","journal-title":"BJU Int."},{"key":"2026060105301018000_67.6.929.39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40658-022-00470-2","article-title":"Method to determine the statistical technical variability of SUV metrics","volume":"9","author":"De Luca","year":"2022","journal-title":"EJNMMI Phys."},{"key":"2026060105301018000_67.6.929.40","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1007\/s10278-024-01104-y","article-title":"An automated deep learning-based framework for uptake segmentation and classification on PSMA PET\/CT imaging of patients with prostate cancer","volume":"37","author":"Li","year":"2024","journal-title":"J Imaging Inform Med."},{"key":"2026060105301018000_67.6.929.41","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3390\/cancers11091282","article-title":"Exploring tumor heterogeneity using PET imaging: the big picture","volume":"11","author":"Bailly","year":"2019","journal-title":"Cancers (Basel)."},{"key":"2026060105301018000_67.6.929.42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/RLU.0000000000002291","article-title":"Prognostic value of volumetric parameters of pretreatment 18F-FDG PET\/CT in esophageal cancer: a systematic review and meta-analysis","volume":"43","author":"Han","year":"2018","journal-title":"Clin Nucl Med."},{"key":"2026060105301018000_67.6.929.43","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2903-7"},{"key":"2026060105301018000_67.6.929.44","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.18.19734"},{"key":"2026060105301018000_67.6.929.45","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/diagnostics11040663","article-title":"Concordance between response assessment using prostate-specific membrane antigen PET and serum prostate-specific antigen levels after systemic treatment in patients with metastatic castration resistant prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Han","year":"2021","journal-title":"Diagnostics (Basel)."},{"key":"2026060105301018000_67.6.929.46","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","article-title":"Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy","volume":"49","author":"Rosar","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301018000_67.6.929.47","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00259-023-06476-x","article-title":"Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry","volume":"51","author":"Burgard","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301018000_67.6.929.48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/MNM.0000000000001370","article-title":"Evaluation of 68Ga-PSMA PET\/CT with volumetric parameters for staging of prostate cancer patients","volume":"42","author":"Aksu","year":"2021","journal-title":"Nucl Med Commun."},{"key":"2026060105301018000_67.6.929.49","doi-asserted-by":"publisher","DOI":"10.1016\/1078-1439(95)00002-Y"},{"key":"2026060105301018000_67.6.929.50","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res."},{"key":"2026060105301018000_67.6.929.51","doi-asserted-by":"crossref","first-page":"101445","DOI":"10.1016\/j.tranon.2022.101445","article-title":"Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: current concepts in imaging and management","volume":"21","author":"Mahajan","year":"2022","journal-title":"Transl Oncol."},{"key":"2026060105301018000_67.6.929.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0174-x"},{"key":"2026060105301018000_67.6.929.53","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270651"},{"key":"2026060105301018000_67.6.929.54","doi-asserted-by":"crossref","first-page":"683793","DOI":"10.3389\/fonc.2021.683793","article-title":"The evolving role of 18F-FDG PET\/CT in diagnosis and prognosis prediction in progressive prostate cancer","volume":"11","author":"Shen","year":"2021","journal-title":"Front Oncol."},{"key":"2026060105301018000_67.6.929.55","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s00259-025-07198-y","article-title":"Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC","volume":"52","author":"Telli","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301018000_67.6.929.56","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268167"},{"key":"2026060105301018000_67.6.929.57","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264402"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:38Z","timestamp":1785269918000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.2967\/jnumed.125.270872"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270872","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}